Aliases & Classifications for Synovitis

MalaCards integrated aliases for Synovitis:

Name: Synovitis 12 73 20 54 6 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2703
MeSH 44 D013585
NCIt 50 C50766
SNOMED-CT 67 268092005
UMLS 70 C0039103

Summaries for Synovitis

Disease Ontology : 12 A connective tissue disease that results in inflammation located in synovial membrane that lines a synovial joint which causes pain and swelling.

MalaCards based summary : Synovitis is related to tenosynovitis and acne, and has symptoms including arthralgia, myalgia and metatarsalgia. An important gene associated with Synovitis is RELN (Reelin), and among its related pathways/superpathways are Innate Immune System and Integrin Pathway. The drugs rituximab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include synovial membrane, bone and bone marrow, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 73 Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints that... more...

Related Diseases for Synovitis

Diseases related to Synovitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 933)
# Related Disease Score Top Affiliating Genes
1 tenosynovitis 31.3 TNF MMP3 IL6 IL1B CRP
2 acne 31.3 TNF IL6 IL1RN IL1B CXCL8
3 hyperostosis 31.2 MMP13 IL18 CXCL8
4 septic arthritis 31.2 TNF MMP3 MMP1 CXCL8 CRP
5 chondrocalcinosis 31.1 MMP3 MMP1 IL1B
6 gout 31.0 TNF IL6 IL1B IL18 CXCL8
7 bursitis 31.0 TNF MMP3 IL6 IL1B CRP
8 hemophilic arthropathy 30.9 TNFSF11 COMP
9 spondylitis 30.9 TNFSF11 TNF IL6 IL1B CRP
10 carpal tunnel syndrome 30.9 IL6 IL1B COMP
11 osteonecrosis 30.8 TNFSF11 TNF IL1B COL2A1
12 spondylarthropathy 30.8 TNF CD163
13 temporal arteritis 30.7 TNF IL6 IL1RN IL1B CRP CD68
14 osteomyelitis 30.7 TNFSF11 TNF IL6 IL1RN IL1B CXCL8
15 pustulosis of palm and sole 30.7 TNF IL1RN CXCL8 CRP
16 pain agnosia 30.7 TNF IL6 IL1B
17 reactive arthritis 30.7 TNF IL6 IL1B CXCL8 CRP COMP
18 spondyloarthropathy 1 30.6 TNFSF11 TNF MMP3 IL6 IL1RN CRP
19 juvenile rheumatoid arthritis 30.6 TNF MMP3 IL6 IL1RN IL1B IL18
20 psoriatic arthritis 30.5 TNFSF11 TNF MMP3 MMP1 IL6 IL1RN
21 arthropathy 30.5 TNFSF11 TNF PRG4 MMP3 MMP13 MMP1
22 rheumatoid arthritis 30.5 VCAM1 TNFSF11 TNF MMP3 MMP13 MMP1
23 lyme disease 30.5 TNF IL6 IL1B CRP
24 uveitis 30.5 TNF IL6 IL1B ICAM1 CXCL8
25 bone resorption disease 30.5 TNFSF11 TNF IL6 IL1B CRP
26 spondyloarthropathy 30.5 VCAM1 TNFSF11 TNF MMP3 IL6 IL1B
27 psoriasis 30.4 VCAM1 TNF IL6 IL1B IL18 ICAM1
28 rubella 30.4 TNF IL6 IL1B
29 syphilis 30.4 TNF IL6 CRP
30 pertussis 30.4 TNF IL6 IL1B CXCL8
31 vasculitis 30.4 VCAM1 TNF IL6 ICAM1 CRP
32 exanthem 30.3 TNF IL6 IL1B IL18 CXCL8 CRP
33 sarcoidosis 1 30.3 TNF IL1RN IL1B IL18 ICAM1 CRP
34 cryoglobulinemia 30.3 TNF IL6 IL1B
35 osteoarthritis 30.3 TNFSF11 TNF PRG4 MMP3 MMP13 MMP1
36 brucellosis 30.3 TNF IL6 IL1RN IL18 CXCL8 CRP
37 leprosy 3 30.2 TNF IL6 IL1B CXCL8 CD68
38 myositis 30.2 TNF IL6 IL1B CXCL8
39 amyloidosis 30.2 TNF IL6 IL1B CRP
40 fibromyalgia 30.2 TNF IL6 IL1B CXCL8 CRP
41 osteochondritis dissecans 30.2 PRG4 MMP3 MMP13 COMP
42 familial mediterranean fever 30.2 TNF IL6 IL1RN IL1B IL18 CXCL8
43 iridocyclitis 30.2 TNF IL6 IL1B CRP
44 urticaria 30.2 TNF IL6 IL18 CXCL8 CRP
45 enterocolitis 30.2 TNF IL6 CXCL8
46 chondromalacia 30.1 TNF IL6 CRP COMP
47 angioimmunoblastic lymphadenopathy with dysproteinemia 30.1 TNF IL6
48 pyoderma gangrenosum 30.1 TNF MMP1 CXCL8
49 autoimmune disease 30.1 VCAM1 TNF IL6 IL1RN IL1B IL18
50 chronic recurrent multifocal osteomyelitis 30.1 TNFSF11 TNF IL6 IL1RN IL1B CRP

Graphical network of the top 20 diseases related to Synovitis:



Diseases related to Synovitis

Symptoms & Phenotypes for Synovitis

UMLS symptoms related to Synovitis:


arthralgia; myalgia; metatarsalgia

MGI Mouse Phenotypes related to Synovitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 COL2A1 COMP ICAM1 IL18 IL1B IL1RN
2 homeostasis/metabolism MP:0005376 10.22 CD163 COL2A1 COMP CRP ICAM1 IL18
3 cardiovascular system MP:0005385 10.21 CD163 COL2A1 COMP CRP ICAM1 IL18
4 immune system MP:0005387 10.19 CD163 CD68 COL2A1 COMP CRP ICAM1
5 hematopoietic system MP:0005397 10.18 CD163 CD68 ICAM1 IL18 IL1B IL1RN
6 integument MP:0010771 9.81 ICAM1 IL18 IL1B IL1RN IL6 MMP13
7 muscle MP:0005369 9.56 CD163 COMP ICAM1 IL18 IL6 RELN
8 skeleton MP:0005390 9.32 CD68 COL2A1 COMP IL1B IL1RN IL6

Drugs & Therapeutics for Synovitis

Drugs for Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4 174722-31-7 10201696
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
4 Adrenocorticotropic Hormone Phase 4
5 Melanocyte-Stimulating Hormones Phase 4
6 beta-Endorphin Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Hormones Phase 4
9 Hormone Antagonists Phase 4
10 glucocorticoids Phase 4
11 Triamcinolone diacetate Phase 4
12 Triamcinolone hexacetonide Phase 4
13 triamcinolone acetonide Phase 4
14 Factor VIII Phase 4
15 Coagulants Phase 4
16 BAX 855 Phase 4
17
Etanercept Approved, Investigational Phase 3 185243-69-0
18
Certolizumab pegol Approved Phase 3 428863-50-7
19
Abatacept Approved Phase 3 332348-12-6 10237
20
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
22
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
24
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
25
Chondroitin Phase 3 9007-27-6 14389182
26 Gastrointestinal Agents Phase 3
27 Anti-Inflammatory Agents, Non-Steroidal Phase 3
28 Analgesics Phase 3
29 Analgesics, Non-Narcotic Phase 3
30 Antiemetics Phase 3
31 Liver Extracts Phase 3
32 Cyclooxygenase Inhibitors Phase 3
33 Analgesics, Opioid Phase 3
34 Antineoplastic Agents, Hormonal Phase 3
35 BB 1101 Phase 3
36 Ketorolac Tromethamine Phase 3
37
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
38
Olaparib Approved Phase 2 763113-22-0 23725625
39
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
45
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
46
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
47
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
48
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
49
Tremelimumab Investigational Phase 2 745013-59-6
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
2 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Unknown status NCT02437461 Phase 4 Triamcinolone hexacetonide
3 Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen Completed NCT01205854 Phase 4
4 Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
5 A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs Completed NCT01034397 Phase 4 tocilizumab [RoActemra/Actemra];placebo;non-biological DMARDs
6 Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging Completed NCT01948388 Phase 4 corticotrophin 80 units
7 Injection After Arthroscopic Partial Meniscectomy Recruiting NCT04641351 Phase 4 Zilretta Injectable Product or Placebo
8 Intensive Replacement Treatment in Haemophilia Patients With Synovitis Not yet recruiting NCT04784988 Phase 4 Adynovate;plasma derived or recombinant products containing FVIII
9 Adipose Derived Stromal Cell Transplantation as an Adjunct to Arthroscopy in Treatment of Effusion Synovitis of the Early Degenerative Knee Suspended NCT03922490 Phase 4
10 Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs Withdrawn NCT01878318 Phase 4 methotrexate;tocilizumab [RoActemra/Actemra]
11 Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee Completed NCT00604539 Phase 3 Chondroitin sulphate (Condrosan);Placebo
12 The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients Completed NCT01213017 Phase 3 certolizumab pegol
13 Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA) Completed NCT00996606 Phase 3 DMARDs;Tocilizumab
14 Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis Completed NCT00522184 Phase 3
15 A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate Completed NCT00420199 Phase 3 Abatacept;Placebo
16 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Active, not recruiting NCT02371369 Phase 3 Pexidartinib;Placebo
17 A Double-blinded, Prospective, Randomized, Controlled Trial Comparing Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders Terminated NCT02266433 Phase 3 Ketorolac;Dexamethasone
18 A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties Completed NCT01272830 Phase 2 Placebo;Apatone®B
19 Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence Completed NCT00678782 Phase 2 etanercept;placebo
20 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
21 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
22 A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) Completed NCT02471716 Phase 1, Phase 2
23 Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis Completed NCT00425932 Phase 2
24 Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy Completed NCT00001677 Phase 2 Methotrexate;Fludarabine
25 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Recruiting NCT03069469 Phase 1, Phase 2 DCC-3014
26 A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors Recruiting NCT02029001 Phase 2 Nilotinib (400 mg BID);Everolimus (10 mg QD);Sorafenib (400 mg BID);Lapatinib (1500 mg QD);Pazopanib (800 mg QD);Olaparib (300 mg BID)
27 MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE Recruiting NCT03355482 Phase 2 Methylprednisolone;Placebos
28 A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting NCT01207492 Phase 2 nilotinib
29 An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee Not yet recruiting NCT04731675 Phase 2
30 Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint Withdrawn NCT01471418 Phase 2 PET/CT with 18-FDG
31 A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Recruiting NCT02060305 Phase 1 Bevacizumab intra-articular injection
32 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) Terminated NCT02673736 Phase 1 PLX73086
33 The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study Unknown status NCT01050010
34 Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series Unknown status NCT03507933
35 Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography Unknown status NCT00903903
36 The Effect on Gait Pattern in Patients Receiving Arthroscopic Cartilage Regeneration Facilitating Procedure (ACRFP) for Treatment of Osteoarthritis Unknown status NCT03452423
37 Musculoskeletal Ultrasound of the Ankles in Erysipelas-like Erythema of Familial Mediterranean Fever Unknown status NCT03917277
38 Correlation of "Painless" Synovitis With Clinical, Laboratory and Radiological (X-ray, Sonography) Finds in Patients With Longstanding Rheumatoid Arthritis (RA). Unknown status NCT01639287
39 A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis Unknown status NCT02339636
40 Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis Unknown status NCT01731262
41 Fibromyalgia-like Joint/Muscle Pain and Synovitis in Non-celiac Wheat Sensitivity Patients Completed NCT03022513
42 Evaluation of the Role of Power Doppler Sonography in the Diagnosis of Hemophilic Joint Disease Completed NCT00212485
43 Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in RA : Cross-sectionnal Study Completed NCT03004651
44 Quantitative Assessment of Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound Completed NCT02902562
45 Physiotherapy in the Treatment of Elbow Hemophilic Arthropathy: Manual Therapy vs Educational Physiotherapy. A Pilot Sudy Completed NCT02198040
46 Effectiveness of Manual Therapy and Educational Physiotherapy in the Treatment of Hemophilic Arthropathy of the Knee. A Randomized Pilot Study Completed NCT02198014
47 Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients Completed NCT04750993
48 The Importance of Immobilisation After Intra-articular Glucocorticoid Treatment for Elbow Synovitis - a Randomised and Controlled Study Completed NCT00972530
49 Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients Completed NCT00001679
50 The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis Completed NCT00001375

Search NIH Clinical Center for Synovitis

Genetic Tests for Synovitis

Anatomical Context for Synovitis

The Foundational Model of Anatomy Ontology organs/tissues related to Synovitis:

19
Synovial Membrane

MalaCards organs/tissues related to Synovitis:

40
Bone, Bone Marrow, Endothelial, Skin, T Cells, Lung, Heart

Publications for Synovitis

Articles related to Synovitis:

(show top 50) (show all 11236)
# Title Authors PMID Year
1
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. 61 54
20436079 2010
2
Haem oxygenase-1 down-regulates high mobility group box 1 and matrix metalloproteinases in osteoarthritic synoviocytes. 54 61
20110250 2010
3
TNF-alpha-induced aquaporin 9 in synoviocytes from patients with OA and RA. 54 61
20181673 2010
4
Expression of aquaporin 1 (AQP1) in human synovitis. 54 61
20149606 2010
5
Immunologic rheumatic disorders. 61 54
20176259 2010
6
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. 61 54
20181277 2010
7
Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. 61 54
19565512 2009
8
Interleukin-6 as a key player in systemic inflammation and joint destruction. 61 54
19189867 2009
9
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. 61 54
19333931 2009
10
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. 61 54
19883500 2009
11
[Content of C-reactive protein, interleukin-1, interleukin-6 and interleukin-1 receptor antagonist in the blood of patients with early osteoarthrosis of the knee joints]. 54 61
19663194 2009
12
Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. 61 54
18762862 2009
13
Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. 61 54
18975340 2008
14
Association of body fat with C-reactive protein in rheumatoid arthritis. 54 61
18759279 2008
15
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? 54 61
18234715 2008
16
Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. 54 61
18578976 2008
17
Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. 54 61
17976692 2008
18
Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. 54 61
18310134 2008
19
Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. 61 54
18311806 2008
20
Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. 61 54
18565244 2008
21
The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. 61 54
18311801 2008
22
[Cartilage oligomeric matrix protein, a possible marker of synovitis in early knee joint osteoarthrosis]. 54 61
19177799 2008
23
Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. 54 61
18582368 2008
24
Anti-inflammatory activity of chondroitin sulfate. 61 54
18667340 2008
25
Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study. 54 61
18346273 2008
26
Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. 54 61
17918786 2007
27
Expression of receptor activator of nuclear factor-kappaB ligand in synovial tissue: comparison with degradation of articular cartilage in temporomandibular joint disorders. 54 61
17560137 2007
28
[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]. 61 54
17642234 2007
29
Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. 54 61
17425385 2007
30
Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. 54 61
17289161 2007
31
Comparison of taurine chloramine and taurine bromamine effects on rheumatoid arthritis synoviocytes. 54 61
16868648 2007
32
Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. 61 54
17397533 2007
33
Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study. 61 54
16670155 2006
34
Inflammation-induced bone loss: can it be prevented? 54 61
17288976 2006
35
Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. 61 54
16901276 2006
36
Pathogenesis of spondyloarthritis: insights from synovial membrane studies. 61 54
16839506 2006
37
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. 61 54
16891219 2006
38
Anti-TNF and sex hormones. 54 61
16855166 2006
39
Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis? 54 61
16205926 2006
40
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 54 61
16542506 2006
41
The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. 61 54
17177994 2006
42
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. 61 54
16282041 2005
43
Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis. 61 54
15843449 2005
44
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 61 54
16329106 2005
45
Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. 54 61
15672235 2005
46
Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. 54 61
16076882 2005
47
Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. 61 54
16142858 2005
48
Immunoglobulin G from anti-glucose-6-phosphate isomerase antibodies positive patient with rheumatoid arthritis induces synovitis in cynomolgus monkeys. 61 54
16137614 2005
49
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. 54 61
16142748 2005
50
Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. 61 54
15986366 2005

Variations for Synovitis

ClinVar genetic disease variations for Synovitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RELN NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly) SNV Pathogenic 684430 rs760019076 GRCh37: 7:103163872-103163872
GRCh38: 7:103523425-103523425

Expression for Synovitis

Search GEO for disease gene expression data for Synovitis.

Pathways for Synovitis

Pathways related to Synovitis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 VCAM1 TNFSF11 TNF MMP3 MMP1 LTB
2
Show member pathways
13.46 VCAM1 PRG4 MMP3 MMP13 MMP1 ICAM1
3
Show member pathways
13.37 VCAM1 TNFSF11 TNF MMP3 MMP1 LTB
4
Show member pathways
13.25 VCAM1 TNF MMP3 MMP1 IL6 IL1B
5
Show member pathways
12.87 TNF IL6 IL1B ICAM1 CXCL8
6
Show member pathways
12.87 TNF IL6 IL1B IL18 ICAM1 CXCL8
7
Show member pathways
12.81 VCAM1 MMP3 MMP13 MMP1 ICAM1 COMP
8
Show member pathways
12.77 TNF IL6 IL1B IL18 CXCL8
9
Show member pathways
12.7 VCAM1 TNFSF11 TNF IL1B ICAM1
10 12.62 VCAM1 TNFSF11 TNF IL1RN IL1B
11
Show member pathways
12.49 TNF IL6 IL1B IL18 CXCL8
12 12.42 TNF IL1B IL18 CXCL8
13
Show member pathways
12.4 TNF IL6 IL1B ICAM1 CRP
14
Show member pathways
12.39 TNF MMP3 MMP13 MMP1 IL6 IL1B
15
Show member pathways
12.36 TNF IL6 IL18 CXCL8
16
Show member pathways
12.31 TNF IL6 IL1B IL18 CXCL8
17
Show member pathways
12.31 TNF IL6 IL1RN IL1B IL18 CXCL8
18 12.3 TNF IL6 IL1B IL18 CXCL8
19 12.28 TNF IL6 IL1B IL18
20 12.25 TNF IL6 IL1RN IL1B CXCL8
21
Show member pathways
12.24 TNF IL6 IL1B CXCL8
22
Show member pathways
12.22 VCAM1 RELN ICAM1 COMP COL2A1
23 12.16 TNF IL6 IL1B IL18 CXCL8
24 12.15 VCAM1 TNF IL1B ICAM1
25 12.09 VCAM1 MMP3 MMP13 ICAM1
26 12.08 TNF LTB IL6 IL1B ICAM1 CXCL8
27 12.06 TNF IL6 CD68 CD163
28 12.05 VCAM1 TNF MMP3 IL6 IL1B ICAM1
29 11.99 TNF IL6 IL1B CXCL8
30
Show member pathways
11.97 TNF MMP3 MMP13 MMP1
31 11.97 VCAM1 TNF IL6 IL1B ICAM1 CXCL8
32 11.97 VCAM1 TNFSF11 TNF LTB IL1B ICAM1
33 11.88 MMP1 IL6 ICAM1 CXCL8
34 11.87 TNF LTB IL1B IL18
35 11.87 VCAM1 TNF MMP3 MMP1 IL6 IL1B
36
Show member pathways
11.84 TNF IL6 IL1B IL18
37 11.84 TNF IL6 IL1B CXCL8
38
Show member pathways
11.83 VCAM1 LTB CXCL8
39
Show member pathways
11.82 TNFSF11 TNF LTB
40 11.82 TNF IL6 IL1B CD163
41 11.78 VCAM1 TNF LTB IL6 ICAM1
42 11.74 TNF IL6 IL1B CXCL8
43 11.73 MMP3 MMP13 MMP1 CXCL8 COL2A1
44 11.69 TNF IL6 IL1B IL18 CXCL8
45
Show member pathways
11.66 VCAM1 TNF MMP3 MMP1 IL6 IL1B
46 11.6 MMP1 IL6 CXCL8
47 11.58 TNFSF11 TNF IL6 IL1B
48 11.57 TNF IL1B IL18
49 11.57 TNF IL6 ICAM1
50 11.56 TNF IL6 IL1RN IL1B IL18 ICAM1

GO Terms for Synovitis

Cellular components related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNFSF11 TNF RELN PRG4 MMP3 MMP13
2 extracellular matrix GO:0031012 9.63 RELN MMP3 MMP13 MMP1 COMP COL2A1
3 extracellular space GO:0005615 9.53 VCAM1 TNFSF11 TNF RELN MMP3 MMP13

Biological processes related to Synovitis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 TNFSF11 TNF IL6 IL1B IL18 CXCL8
2 inflammatory response GO:0006954 9.92 TNF IL6 IL1RN IL1B IL18 CXCL8
3 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 IL1B ICAM1 CXCL8 CD68
4 cartilage development GO:0051216 9.85 MMP13 COMP COL2A1
5 regulation of insulin secretion GO:0050796 9.85 TNF IL6 IL1B
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF IL6 IL18
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNFSF11 TNF IL6 IL1B
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNFSF11 TNF IL6 IL1B IL18 ICAM1
9 cellular response to organic cyclic compound GO:0071407 9.84 TNF IL1B IL18
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF IL1B IL18
11 response to glucocorticoid GO:0051384 9.83 TNF IL6 IL1RN
12 extracellular matrix disassembly GO:0022617 9.83 MMP3 MMP13 MMP1
13 positive regulation of interferon-gamma production GO:0032729 9.82 TNF IL1B IL18
14 positive regulation of T cell proliferation GO:0042102 9.82 VCAM1 IL6 IL1B
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 TNF IL6 IL18
16 immune response GO:0006955 9.81 TNFSF11 TNF PRG4 LTB IL6 IL1RN
17 positive regulation of interleukin-8 production GO:0032757 9.8 TNF IL6 IL1B
18 positive regulation of protein complex assembly GO:0031334 9.8 TNF MMP3 MMP1
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IL1B ICAM1
20 collagen catabolic process GO:0030574 9.77 MMP3 MMP13 MMP1
21 acute-phase response GO:0006953 9.76 IL6 IL1RN CRP CD163
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.75 TNF IL1B COL2A1
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 TNF IL1B IL18
24 negative regulation of neurogenesis GO:0050768 9.71 TNF IL6 IL1B
25 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
26 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.69 TNF IL6 ICAM1
27 regulation of neuroinflammatory response GO:0150077 9.68 MMP3 IL6
28 cellular response to UV-A GO:0071492 9.68 MMP3 MMP1
29 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
30 growth plate cartilage development GO:0003417 9.67 MMP13 COMP
31 negative regulation of lipid storage GO:0010888 9.65 TNF IL6 CRP
32 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.63 IL6 IL1RN
33 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.62 IL1B IL18
34 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
35 membrane to membrane docking GO:0022614 9.61 VCAM1 ICAM1
36 vascular endothelial growth factor production GO:0010573 9.61 TNF IL6 IL1B
37 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IL1B
39 positive regulation of neuroinflammatory response GO:0150078 9.56 TNF IL6 IL1B IL18
40 extracellular matrix organization GO:0030198 9.56 VCAM1 TNF MMP3 MMP13 MMP1 ICAM1
41 cytokine-mediated signaling pathway GO:0019221 9.36 VCAM1 TNFSF11 TNF MMP3 MMP1 IL6

Molecular functions related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.46 VCAM1 IL1B ICAM1 COMP
2 cytokine activity GO:0005125 9.23 TNFSF11 TNF LTB IL6 IL1RN IL1B
3 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF11 TNF LTB

Sources for Synovitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....